Eye最新文献

英文中文

An educational figure of nystagmus. 眼球震颤的教育人物。

IF 3.2 3区医学 Q1 OPHTHALMOLOGY

Eye

Pub Date : 2026-02-13 DOI: 10.1038/s41433-026-04294-7

Yu Jia, Yuping Wang, Liankun Ren

引用次数: 0

Comment on: "Ophthalmic complications associated with COVID-19: a large US national database analysis". 评论：“与COVID-19相关的眼部并发症：美国大型国家数据库分析”。

IF 3.2 3区医学 Q1 OPHTHALMOLOGY

Eye

Pub Date : 2026-02-13 DOI: 10.1038/s41433-026-04290-x

Nir Zontag, Alex V Levin

引用次数: 0

Ultra-high-resolution visualisation of the human ciliary body using Hierarchical Phase-Contrast Tomography (HiP-CT). 使用分层相衬断层扫描（HiP-CT）实现人体纤毛体的超高分辨率可视化。

IF 3.2 3区医学 Q1 OPHTHALMOLOGY

Eye

Pub Date : 2026-02-13 DOI: 10.1038/s41433-026-04300-y

Theresa Urban, Karla Orsine Murta Dias, Harry Petrushkin

引用次数: 0

Pseudopodia lentis and preretinal deposit in systemic amyloidosis. 系统性淀粉样变性的假足扁豆和视网膜前沉积。

IF 3.2 3区医学 Q1 OPHTHALMOLOGY

Eye

Pub Date : 2026-02-13 DOI: 10.1038/s41433-026-04259-w

Yu-Chieh Wu, Yu-Bai Chou

引用次数: 0

Type 1 macular neovascularisation associated with choroidal artery compression. 1型黄斑新生血管形成伴脉络膜动脉受压。

IF 3.2 3区医学 Q1 OPHTHALMOLOGY

Eye

Pub Date : 2026-02-13 DOI: 10.1038/s41433-026-04291-w

Marion Sagnard, Hussam El Chehab

引用次数: 0

Tubercular serpiginous-like choroiditis. 结核蛇形样脉络膜炎。

IF 3.2 3区医学 Q1 OPHTHALMOLOGY

Eye

Pub Date : 2026-02-11 DOI: 10.1038/s41433-026-04293-8

Jessica Galvan, Mateus Lins Dos Santos, Ricardo Luz Leitão Guerra

引用次数: 0

Comment on: 'Management of uveitic and chorioretinal conditions in pregnancy'. 评论：“妊娠期视网膜和绒毛膜视网膜疾病的处理”。

IF 3.2 3区医学 Q1 OPHTHALMOLOGY

Eye

Pub Date : 2026-02-11 DOI: 10.1038/s41433-026-04301-x

Haoxuan Yan

引用次数: 0

Comparative effectiveness of varying hyperbaric oxygen protocols in the treatment of acute central retinal artery occlusion. 不同高压氧方案治疗急性视网膜中央动脉闭塞的比较效果。

IF 3.2 3区医学 Q1 OPHTHALMOLOGY

Eye

Pub Date : 2026-02-10 DOI: 10.1038/s41433-026-04298-3

Ivan Gur, Inbar Gur, Michael Gitzman, Leah Atal, Yinnon Matsliah, Elie Zaher, Nitsan Duvdevan-Strier, Yuval Nov

Background: The comparative effectiveness of different hyperbaric oxygen (HBO) therapy doses in the acute treatment of central retinal artery occlusion (CRAO) has not been evaluated.

Methods: This retrospective cohort study aimed to compare the efficacy of an initial 2.8_ATA HBO session (HBO18) to the more prevalent 2.0_ATA protocol (HBO10). Excluded were patients with suspected inflammatory arteritis or branch retinal artery occlusion, and when HBO was medically contraindicated. Following the initial session, all patients completed two additional HBO10 sessions within 24 h. The primary outcome was the change in best corrected visual acuity (ΔBCVA) within 24 ± 4 h. Safety outcomes included neurological events suggestive of central oxygen toxicity and barotrauma-related symptoms.

Results: Improvement in ΔBCVA was significantly greater in the HBO18 group (median 0.62 LogMAR, mean -0.81 ± 0.73) compared with the HBO10 group (median 0.22 LogMAR, mean -0.34 ± 0.40, p < 0.001). Adverse events were similar in incidence between the treatment groups, with no severe occurrences necessitating the discontinuation of HBO reported. In multivariate analysis, HBO18 use was associated with a 0.5 LogMAR improvement in BCVA at 24 h (95% CI 0.3-0.7, p < 0.001), with greater initial BCVA impairment and shorter time to HBO further associated with better outcomes (0.20 LogMAR, 95% CI 0.08-0.31, p = 0.001; and 0.04 LogMAR/hour, 95% CI 0.02-0.04, p = 0.01, respectively).

Conclusions: HBO18 as the initial therapy for CRAO seems to be associated with better short-term improvement in BCVA, compared with HBO10.

背景：不同高压氧（HBO）治疗剂量在急性视网膜中央动脉闭塞（CRAO）治疗中的比较效果尚未得到评价。方法：本回顾性队列研究旨在比较初始2.8ATA HBO会话（HBO18）与更流行的2.0ATA协议（HBO10）的疗效。排除疑似炎性动脉炎或视网膜分支动脉闭塞的患者，以及医学禁忌的患者。在初始疗程后，所有患者在24小时内完成了两次额外的HBO10疗程。主要观察指标为24±4 h内最佳矫正视力（ΔBCVA）的变化。安全性结果包括提示中枢氧毒性的神经事件和气压损伤相关症状。结果：与HBO10组（中位数0.22 LogMAR，平均值-0.34±0.40,p）相比，HBO18组（中位数0.62 LogMAR，平均值-0.81±0.73）对ΔBCVA的改善显著更大。结论：与HBO10相比，HBO18作为CRAO的初始治疗似乎与BCVA更好的短期改善相关。

{"title":"Comparative effectiveness of varying hyperbaric oxygen protocols in the treatment of acute central retinal artery occlusion.","authors":"Ivan Gur, Inbar Gur, Michael Gitzman, Leah Atal, Yinnon Matsliah, Elie Zaher, Nitsan Duvdevan-Strier, Yuval Nov","doi":"10.1038/s41433-026-04298-3","DOIUrl":"https://doi.org/10.1038/s41433-026-04298-3","url":null,"abstract":"Background: The comparative effectiveness of different hyperbaric oxygen (HBO) therapy doses in the acute treatment of central retinal artery occlusion (CRAO) has not been evaluated.Methods: This retrospective cohort study aimed to compare the efficacy of an initial 2.8ATA HBO session (HBO18) to the more prevalent 2.0ATA protocol (HBO10). Excluded were patients with suspected inflammatory arteritis or branch retinal artery occlusion, and when HBO was medically contraindicated. Following the initial session, all patients completed two additional HBO10 sessions within 24 h. The primary outcome was the change in best corrected visual acuity (ΔBCVA) within 24 ± 4 h. Safety outcomes included neurological events suggestive of central oxygen toxicity and barotrauma-related symptoms.Results: Improvement in ΔBCVA was significantly greater in the HBO18 group (median 0.62 LogMAR, mean -0.81 ± 0.73) compared with the HBO10 group (median 0.22 LogMAR, mean -0.34 ± 0.40, p < 0.001). Adverse events were similar in incidence between the treatment groups, with no severe occurrences necessitating the discontinuation of HBO reported. In multivariate analysis, HBO18 use was associated with a 0.5 LogMAR improvement in BCVA at 24 h (95% CI 0.3-0.7, p < 0.001), with greater initial BCVA impairment and shorter time to HBO further associated with better outcomes (0.20 LogMAR, 95% CI 0.08-0.31, p = 0.001; and 0.04 LogMAR/hour, 95% CI 0.02-0.04, p = 0.01, respectively).Conclusions: HBO18 as the initial therapy for CRAO seems to be associated with better short-term improvement in BCVA, compared with HBO10.","PeriodicalId":12125,"journal":{"name":"Eye","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selective laser trabeculoplasty: adverse effects of prior topical anti-glaucoma medication. 选择性激光小梁成形术：既往局部抗青光眼药物的不良反应。

IF 3.2 3区医学 Q1 OPHTHALMOLOGY

Eye

Pub Date : 2026-02-10 DOI: 10.1038/s41433-026-04273-y

Toby S Al-Mugheiry, Ian Nunney, David C Broadway

Objectives: To determine the long-term effect of the administration of topical anti-glaucoma medications on Selective Laser Trabeculoplasty (SLT) efficacy and to identify other potential risk factors for failure of SLT.

Methods: A single-centre, observational cohort study of 264 SLT procedures performed on 127 patients over a 10-year period. Data collected included the absolute number of anti-glaucoma drops administered, intraocular pressure (IOP) and the number of anti-glaucoma medications at each visit. A Cox's proportional hazards regression analysis was performed to analyse various risk factors. A multivariate logistic regression model for failure in the first 12 months was constructed to adjust for potential confounders, including age, pre-SLT IOP, treatment duration, disease duration, total number of pre-SLT drops administered and SLT energy delivered.

Results: A greater number of pre-SLT drop administrations was identified as a risk factor for failure of SLT. At 12 months, the complete success rate of SLT for eyes unexposed to drops was 62%, for those to a moderate number of drops, 36-41% and for those to a high number of drops, only 2%. Other statistically significant risk factors included duration of drop therapy, exposure to drop preservatives, disease duration, age, previous cataract surgery, lower pre-SLT IOP and a lower SLT energy level.

Conclusions: Long-term exposure to topical anti-glaucoma medication (especially if preserved), longer duration of disease and therapy, together with older age and prior cataract surgery, may all have a significant adverse effect on SLT outcome.

目的：确定局部抗青光眼药物对选择性激光小梁成形术（SLT）疗效的长期影响，并确定SLT失败的其他潜在危险因素。方法：一项单中心、观察性队列研究，在10年期间对127例患者进行264例SLT手术。收集的数据包括每次就诊时抗青光眼滴眼液的绝对数量、眼压（IOP）和抗青光眼药物的数量。采用Cox比例风险回归分析分析各危险因素。建立了前12个月治疗失败的多变量logistic回归模型，以调整潜在的混杂因素，包括年龄、SLT前IOP、治疗持续时间、疾病持续时间、SLT前滴药总数和SLT能量输送。结果：大量的SLT前滴药被确定为SLT失败的危险因素。在12个月时，未接触滴眼液的眼睛的SLT完全成功率为62%，中度滴眼液的成功率为36-41%，而高度滴眼液的成功率仅为2%。其他具有统计学意义的危险因素包括滴眼液治疗持续时间、滴眼液防腐剂暴露、疾病持续时间、年龄、既往白内障手术、SLT前较低的IOP和较低的SLT能量水平。结论：长期接受局部抗青光眼药物治疗（特别是保留治疗），病程和治疗时间较长，加上年龄较大和既往白内障手术，都可能对SLT结果产生显著的不良影响。

{"title":"Selective laser trabeculoplasty: adverse effects of prior topical anti-glaucoma medication.","authors":"Toby S Al-Mugheiry, Ian Nunney, David C Broadway","doi":"10.1038/s41433-026-04273-y","DOIUrl":"https://doi.org/10.1038/s41433-026-04273-y","url":null,"abstract":"Objectives: To determine the long-term effect of the administration of topical anti-glaucoma medications on Selective Laser Trabeculoplasty (SLT) efficacy and to identify other potential risk factors for failure of SLT.Methods: A single-centre, observational cohort study of 264 SLT procedures performed on 127 patients over a 10-year period. Data collected included the absolute number of anti-glaucoma drops administered, intraocular pressure (IOP) and the number of anti-glaucoma medications at each visit. A Cox's proportional hazards regression analysis was performed to analyse various risk factors. A multivariate logistic regression model for failure in the first 12 months was constructed to adjust for potential confounders, including age, pre-SLT IOP, treatment duration, disease duration, total number of pre-SLT drops administered and SLT energy delivered.Results: A greater number of pre-SLT drop administrations was identified as a risk factor for failure of SLT. At 12 months, the complete success rate of SLT for eyes unexposed to drops was 62%, for those to a moderate number of drops, 36-41% and for those to a high number of drops, only 2%. Other statistically significant risk factors included duration of drop therapy, exposure to drop preservatives, disease duration, age, previous cataract surgery, lower pre-SLT IOP and a lower SLT energy level.Conclusions: Long-term exposure to topical anti-glaucoma medication (especially if preserved), longer duration of disease and therapy, together with older age and prior cataract surgery, may all have a significant adverse effect on SLT outcome.","PeriodicalId":12125,"journal":{"name":"Eye","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between PCSK9 inhibitor use and risk of age-related macular degeneration. PCSK9抑制剂的使用与年龄相关性黄斑变性风险的关系

IF 3.2 3区医学 Q1 OPHTHALMOLOGY

Eye

Pub Date : 2026-02-10 DOI: 10.1038/s41433-026-04287-6

Jaffer Shah, Lili Gerendás, Henriette Serhan, Harris Ahmed, Muhamad Festok, M Abdallah Mahrous, Kyle D Kovacs, Szilárd Kiss

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Eye

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀